



PerkinElmer and M. D. Anderson Cancer Center Collaborate

WALTHAM, Mass. – PerkinElmer, Inc., a global leader in Health Sciences, today announced an arrangement with The University of Texas M. D. Anderson Cancer Center that will bring PerkinElmer's Array Comparative Genomic Hybridization (aCGH) to the cancer center. aCGH is analogous to traditional karyotyping but with greater throughput, resolution and ease of use.

A unique component to the arrangement is that PerkinElmer will train the facility's Molecular Genetic Technology (MGT) students in the aCGH technique. PerkinElmer will also support two student research projects for presentation at genomics and cytogenetics conferences to increase the medical community's understanding of the utility of Array CGH.

"We were thrilled to forge a relationship with M. D. Anderson to support their cancer research and train their technologists in this powerful technique," said Ann-Christine Sundell, President, Genetic Screening, PerkinElmer.

"The MGT students at M. D. Anderson will benefit from this learning experience via a hands-on perspective," says Peter Hu, Ph.D., Director for the MGT program.

"We felt this venture was such a win-win situation for everyone involved," says Alan Lennon, Ph.D., education coordinator for the MGT program.

The technique will allow scientists to learn more cytogenetically about samples in less time, enabling researchers to advance the pace of their cancer research.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) markets into which we sell our products decline or do not grow as anticipated; (4) our failure to adequately protect our intellectual property; (5) the loss of any of our licenses or licensed rights; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to produce an adequate quantity of products to meet our customers' demands; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with health care industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) restrictions in our credit agreements; (18) our ability to realize the full value of our intangible assets; and (19) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:
Ellen Wein

(412) 456-0986